Clinical effect of increasing doses of lenalidomide in high-risk myelodysplastic syndrome and acute myeloid leukemia with chromosome 5 abnormalities

Background Patients with chromosome 5 abnormalities and high-risk myelodysplastic syndromes or acute myeloid leukemia have a poor outcome. We hypothesized that increasing doses of lenalidomide may benefit this group of patients by inhibiting the tumor clone, as assessed by fluorescence in situ hybri...

Повний опис

Бібліографічні деталі

Автори:	Lars Möllgård, Leonie Saft, Marianne Bach Treppendahl, Ingunn Dybedal, Jan Maxwell Nørgaard, Jan Astermark, Elisabeth Ejerblad, Hege Garelius, Inge Høgh Dufva, Monika Jansson, Martin Jädersten, Lars Kjeldsen, Olle Linder, Lars Nilsson, Hanne Vestergaard, Anna Porwit, Kirsten Grønbæk, Eva Hellström Lindberg
Формат:	Artigo
Мова:	Inglês
Опубліковано:	Ferrata Storti Foundation 2011-07-01
Серія:	Haematologica
Онлайн доступ:	https://haematologica.org/article/view/6025
Теги:	Додати тег Немає тегів, Будьте першим, хто поставить тег для цього запису!